№ lp_1_13329
File format: docx
Character count: 39001
File size: 236 KB
This PGD outlines the administration procedures for inactivated influenza vaccine as part of the national immunisation programme for the 2025–2026 season in England.
Year:
2025
Region / city:
England
Topic:
Influenza immunisation
Document type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Jamie Lopez-Bernal, Greta Hayward
Target audience:
Healthcare practitioners, NHS organisations
Period of validity:
From 1 September 2025 to 1 April 2026
Approval date:
3 July 2025
Revision history:
Updated annually, latest update 9 July 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / city:
Northern Ireland
Subject:
Influenza vaccination
Document type:
Protocol
Organization / institution:
Public Health Agency (PHA)
Author:
Strategic Planning and Performance Group (SPPG)
Target audience:
Healthcare professionals
Period of validity:
1 September 2025 - 1 April 2026
Approval date:
03/09/25
Note:
Change history
Version 1.0:
New national protocol for inactivated influenza vaccine, 6 October 2021
Version 2.0:
Eligibility and vaccine details update for 2022-2023, 26 August 2022
Version 3.0:
Eligibility update for 2024-2025, 8 August 2024
Version 4.0:
Update with eligibility criteria for 2025-2026, 13 August 2025
Date of amendments:
Various
Expiration date:
1 April 2026
Year:
2025
Region / city:
United Kingdom
Topic:
Vaccination
Document type:
Protocol
Organ / institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare providers involved in influenza vaccination
Effective period:
From 1 September 2025 to 1 April 2026
Approval date:
28 July 2025
Amendment dates:
7 December 2020, 17 July 2023, 20 June 2024, 9 July 2025
Year:
2025
Region / city:
[insert local health board name]
Theme:
Vaccination
Document type:
Patient Group Direction (PGD)
Authorising organisation:
NHS Wales
Target audience:
Healthcare professionals (Registered)
Period of validity:
01 September 2025 - 31 March 2026
Approval date:
07 August 2025
Amendment date:
30 June 2025
Review date:
01 July 2026
Expiry date:
31 March 2026
Year:
2025
Region / city:
Wales
Topic:
Inactivated influenza vaccine administration
Document type:
Addendum
Organization / institution:
NHS Wales
Author:
Welsh Medicines Advice Service (WMAS)
Target audience:
Registered healthcare professionals
Period of validity:
01 September 2025 - 31 March 2026
Approval date:
05 November 2025
Review date:
01 July 2026
Version:
1.0
Approval body:
Vaccine Clinical Advisory Group (VCAG)
Expiry date:
31 March 2026
Additional references:
Welsh Government. Health circulars. Available from https://www.gov.wales/health-circulars
Note:
[accessed 22 September 2025]
Context description:
Addendum to the NHS Wales Patient Group Direction (PGD) outlining the guidelines for administering inactivated influenza vaccines for the National Immunisation Programme 2025-2026.
Year:
2025
Region / City:
England
Topic:
Immunisation
Document Type:
Patient Group Direction (PGD)
Organisation / Institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Rebecca Cordery, Greta Hayward
Target Audience:
Healthcare practitioners
Period of Validity:
From 1 November 2025 to 1 November 2028
Approval Date:
24 September 2025
Revision Date:
23 September 2025
Year:
2025
Region / city:
Northern Ireland
Subject:
Influenza vaccination
Document type:
Protocol
Organization / institution:
Public Health Agency (PHA)
Author:
Strategic Planning and Performance Group (SPPG)
Target audience:
Healthcare professionals
Period of validity:
1 September 2025 - 1 April 2026
Approval date:
03/09/25
Note:
Change history
Version 1.0:
New national protocol for inactivated influenza vaccine, 6 October 2021
Version 2.0:
Eligibility and vaccine details update for 2022-2023, 26 August 2022
Version 3.0:
Eligibility update for 2024-2025, 8 August 2024
Version 4.0:
Update with eligibility criteria for 2025-2026, 13 August 2025
Date of amendments:
Various
Expiration date:
1 April 2026
Year:
2025–2026
Country:
Wales
Healthcare system:
NHS Wales
Document type:
Patient Group Direction
Clinical area:
Immunisation
Vaccine:
Inactivated Influenza Vaccine
Service:
Primary Care Contractor Service: Immunisation (PCCS:I)
Setting:
Community Pharmacy
Operational period start:
01 September 2025
Review date:
01 July 2026
Expiry date:
31 March 2026
Version:
4.0
Legal framework:
Human Medicines Regulations 2012
Developing organisation:
Welsh Medicines Advice Service
Commissioning bodies:
Local Health Boards in Wales
Authoring body:
NHS Wales
Target professionals:
Registered pharmacy professionals
Professional registration:
General Pharmaceutical Council
Approval date (CPCAG):
10 July 2025
Ratification date (All Wales PGD Advisory Board):
16 July 2025
Governance responsibility:
Local Health Boards
Source type:
Official clinical governance document
Year:
2025
Region / city:
United Kingdom
Topic:
Vaccination
Document type:
Protocol
Organ / institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare providers involved in influenza vaccination
Effective period:
From 1 September 2025 to 1 April 2026
Approval date:
28 July 2025
Amendment dates:
7 December 2020, 17 July 2023, 20 June 2024, 9 July 2025
National reference:
CYM-24018
Local reference:
CYM-24018
Type of document:
Patient Group Direction
Vaccine:
Inactivated influenza vaccine
Programme:
National Influenza Immunisation Programme 2024–2025
Operational period:
01 September 2024 – 31 March 2025
Valid from:
01 September 2024
Review date:
01 July 2025
Expiry date:
31 March 2025
Version:
2.0
Developing organisation:
Welsh Medicines Advice Service
Health system:
NHS Wales
Geographical scope:
Wales
Legal framework:
Human Medicines Regulations 2012, Schedule 16 Part 2
Target professionals:
Registered healthcare professionals authorised under a PGD
Author:
Welsh Medicines Advice Service
Main author:
Dianne Burnett
Peer review body:
Vaccine Clinical Advisory Group
Ratifying body:
All Wales PGD Advisory Board
Date of VCAG approval:
18 July 2024
Date of ratification:
26 July 2024
Subject area:
Immunisation and vaccination policy
Clinical focus:
Seasonal influenza vaccination
Source type:
Clinical governance and medicines administration directive
Year:
2023
Region / city:
United Kingdom
Theme:
Immunisation
Document type:
Protocol
Organ / institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in influenza vaccination
Period of validity:
1 September 2023 – 1 April 2024
Approval date:
31 July 2023
Date of amendments:
17 July 2023
Version:
05.00
Expiry date:
1 April 2024
Responsible body:
Department of Health and Social Care Ministers
Clinical supervisor requirements:
Registered doctor, nurse or pharmacist
Indemnity cover required:
Yes
Training requirements:
Competency in protocol
Vaccination pathway:
Staff may work in multiple stages
Document version history:
Available
Contact for inquiries:
[email protected]
Change history:
Includes updates for 2023-2024 season, Shingrix co-administration advice
Year:
2020
Region / city:
Australia
Subject:
Influenza Vaccination
Document Type:
Resubmission for listing
Agency / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Sanofi-Aventis Australia Pty Ltd
Target Audience:
Healthcare providers, public health authorities
Period of validity:
From 2020 onward
Approval Date:
July 2019
Date of amendments:
July 2019
Year:
2017
Country:
Australia
Vaccine type:
Inactivated trivalent influenza vaccine (TIV-HD)
Manufacturer:
Sanofi-Aventis Australia Pty Ltd
Product form:
Suspension for injection, 180mcg single dose in 0.5mL
Regulatory approval:
TGA registration December 2017
Target population:
Persons aged 65 years and older
Purpose:
Listing on National Immunisation Program (NIP)
Comparative analysis:
Cost-minimisation versus standard quadrivalent influenza vaccine (QIV)
Advisory review:
PBAC and ATAGI evaluation
Implementation considerations:
Cold chain capacity, provider communication, monitoring adverse events
Year:
2015
Region / city:
United Kingdom
Topic:
Immunisation
Document type:
Public Health Guideline
Organization / institution:
Public Health England
Author:
Elizabeth Graham, Mary Ramsay, David Green
Target audience:
Healthcare professionals, Registered Nurses, Paramedics
Period of validity:
From 15 December 2015 to 30 November 2017
Approval date:
15 December 2015
Amendment date:
N/A
Expiry date:
30 November 2017
Version:
v01.00
Review date:
1 June 2017
Reference number:
DTaP/IPV/Hib PGD
Note:
Change history
Version 1.00:
New PHE PGD template, 15 December 2015
Year:
2021
Region / city:
United Kingdom
Theme:
Health, Immunisation
Document Type:
Patient Group Direction (PGD)
Organisation:
UK Health Security Agency (UKHSA)
Author:
Elizabeth Graham, Mary Ramsay, David Green
Target Audience:
Healthcare providers, community pharmacies
Period of Validity:
21 October 2021 – 31 March 2022
Approval Date:
21 October 2021
Amendment Date:
12 October 2021
Expiration Date:
31 March 2022
Version:
v09.00
Change History:
Includes amendments to reflect current influenza vaccination programme and updates related to healthcare professionals and drug interactions
Context:
A guideline for healthcare professionals to administer the inactivated influenza vaccine under the NHS seasonal influenza vaccination service, developed and authorised by UKHSA.
Year:
2021
Region / Country:
United States
Subject:
Influenza vaccination
Document Type:
Vaccine Information Statement
Issuing Organization:
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
Target Audience:
General public, children, pregnant individuals, older adults, people with chronic conditions
Vaccine Type:
Inactivated or Recombinant Influenza Vaccine
Administration Period:
Annual flu season (October–May)
Possible Reactions:
Soreness, redness, swelling, fever, muscle aches, headache, fainting, rare Guillain-Barré Syndrome
Reporting System:
Vaccine Adverse Event Reporting System (VAERS)
Compensation Program:
National Vaccine Injury Compensation Program (VICP)
Guidance Source:
FDA, CDC
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Reference no:
HPV (GBMSM) PGD
Version no:
v5.0
Valid from:
1 September 2025
Review date:
1 April 2028
Expiry date:
1 September 2028
Author:
Suki Hunjunt, Sharif Ismail, David Green
Region / city:
England
Target audience:
Healthcare practitioners administering HPV vaccine to GBMSM
Type of document:
Patient Group Direction
Organisation:
UK Health Security Agency (UKHSA)
Date of approval:
17 July 2025
Date of modifications:
16 July 2025
Context:
A formal Patient Group Direction for the administration of HPV vaccine to GBMSM, detailing legal, clinical, and procedural requirements for healthcare practitioners in England.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region:
England
Subject:
Hepatitis B vaccination for renal patients
Document Type:
Patient Group Direction (PGD)
Authorising Organisation:
UK Health Security Agency (UKHSA)
Target Audience:
Registered healthcare professionals
Period of Validity:
28 February 2025 - 28 February 2028
Approval Date:
28 February 2025
Amendment Date:
21 February 2025
Year:
2024
Region / city:
England
Topic:
Vaccination
Document type:
Patient Group Direction
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, David Green
Target audience:
Registered healthcare practitioners
Period of validity:
10 October 2024 - 30 April 2027
Approval date:
4 October 2024
Amendments date:
9 October 2024